Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...

Patients carrying 2 copies of the APOE4 gene (APOE4/4 homozygotes) are more likely to develop AD earlier in life than those without APOE4.

APOE ε4 carrier status may be a genetic risk factor for vulnerability to negative anticholinergic effects. There is no clinically available laboratory test to assess anticholinergic levels.

“A precision medicine approach is key to addressing the needs of Alzheimer’s patients who have the ApoE4/4 genotype, and we are committed to this patient population,” she said. A long-term ...

The APOE region or locus is a segment of DNA with several genes in close apposition, including APOE. Its boundaries are not strictly defined, spanning a stretch between 0.2 and 10 Mb long. In 5’ to 3’ ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help ...